New Alzheimer’s drug unexpectedly approved in China

This is the first new treatment to reach the market in almost 20 years. The drug uses a completely different pathway than any before it. It “is suggested to reduce neuroinflammation by modulating a person’s gut microbiome.” After a 9-month Phase III clinical trial the drug was approved with some limitations. There’s still a healthy dose of skepticism around it’s long-term value, though. | learn more